An umbrella review of systematic reviews on the impact of the COVID-19 pandemic on cancer prevention and management, and patient needs

Ref ID 893
First Author T. Muka
Journal ELIFE
Year Of Publishing 2023
URL https://elifesciences.org/articles/85679
Keywords Protocols
Transparency
COVID
Oncology
Risk of bias
Disclosure
Non-Cochrane reviews
Low methodological quality
Problem(s) Reasons for excluding potentially eligible studies not provided
Conflicts of interest or funding of included studies not assessed
Risk of bias not incorporated into conclusions of review
Low methodological (AMSTAR) quality
No registered or published protocol
Number of systematic reviews included 52
Summary of Findings From 52 included systematic reviews on impact of the COVID-19 pandemic on cancer treatment modification, delays, and cancellations indexed across PubMed and WHO COVID-19 up to November 2022. Only two reviews scored moderate to high methodological quality using AMSTAR-2, while the rest (43/52; 82.6%) were evaluated as low or critically low quality. Almost half of the included reviews (25/50; 48.0%) did not report a protocol; only 3 provided a list of excluded studies (5.7%) and just 4 reported on sources of funding of included studies (7.6%); an assessment of risk in individual studies when interpreting/discussing the results was only carried out in 8 reviews (15.3%).
Did the article find that the problem(s) led to qualitative changes in interpretation of the results? Not Applicable
Are the methods of the article described in enough detail to replicate the study? No